Michael S. Hearne is the CFO & Sec. at La Jolla Pharmaceutical Co.
As the CFO & Sec. of La Jolla Pharmaceutical Co, the total compensation of Mr Hearne at La Jolla Pharmaceutical Co is $186,039. There are 2 executives at La Jolla Pharmaceutical Co getting paid more, with Larry G. Edwards having the highest compensation of $749,170.
Mr Hearne is 58, he's been the CFO & Sec. of La Jolla Pharmaceutical Co since . There are 2 older and 8 younger executives at La Jolla Pharmaceutical Co. The oldest executive at La Jolla Pharmaceutical Co. is Robert Rosen, 64, who is the Independent Director.
Michael's mailing address filed with the SEC is 4747 Executive Dr, San Diego, CA 92121, USA.
Over the last 21 years, insiders at La Jolla Pharmaceutical Co have traded over $13,460,170 worth of La Jolla Pharmaceutical Co stock and bought 11,640,515 units worth $137,250,039 . The most active insiders traders include Advisors Llcperceptive Life..., James N Topper e Woodlands Health Ventures F.... On average, La Jolla Pharmaceutical Co executives and independent directors trade stock every 63 days with the average trade being worth of $1,249,971. The most recent stock trade was executed by Craig A Johnson on 8 July 2022, trading 12,000 units of LJPC stock currently worth $47,160.
La Jolla Pharmaceutical Company is dedicated to the development and commercialization of innovative therapies that improve outcomes in patients suffering from life-threatening diseases. In December 2017, GIAPREZA™ (angiotensin II) was approved by the U.S. Food and Drug Administration (FDA) as a vasoconstrictor indicated to increase blood pressure in adults with septic or other distributive shock. In August 2019, GIAPREZA was approved by the European Commission (EC) for the treatment of refractory hypotension in adults with septic or other distributive shock who remain hypotensive despite adequate volume restitution and application of catecholamines and other available vasopressor therapies. LJPC-0118 (artesunate) is La Jolla's investigational product for the treatment of severe malaria.
La Jolla Pharmaceutical Co executives and other stock owners filed with the SEC include: